Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).

医学 细胞因子释放综合征 中性粒细胞减少症 氟达拉滨 阿勒姆图祖马 来那度胺 内科学 发热性中性粒细胞减少症 多发性骨髓瘤 胃肠病学 肿瘤溶解综合征 环磷酰胺 化疗 嵌合抗原受体 免疫疗法 移植 癌症
作者
Sham Mailankody,Andrzej Jakubowiak,Myo Htut,Luciano J. Costa,Kelvin Lee,Siddhartha Ganguly,Jonathan L. Kaufman,David S. Siegel,William Bensinger,Mariana Cota,Thomas Doerr,Todd DeVries,Sandy W. Wong
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:38 (15_suppl): 8504-8504 被引量:125
标识
DOI:10.1200/jco.2020.38.15_suppl.8504
摘要

8504 Background: Orva-cel is an investigational, BCMA-directed CAR T cell product with a fully human binder. Over 100 pts have been treated in the EVOLVE phase 1 study. Pts treated at 50 and 150 × 106 CAR+ T cells were previously reported (Mailankody ASH 2018 #957). We now report results of the higher dose levels (DLs) in 51 pts who received orva-cel manufactured using the process intended to support commercial use. Methods: Pts with RRMM who had ≥3 prior regimens, a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody (mAb), received orva-cel at 300, 450, and 600 × 106 CAR+ T cells after lymphodepletion with fludarabine/cyclophosphamide. Results: Median pt age was 61 (range, 33–77) y; median time from diagnosis was 7.0 (range, 1.7–23.6) y, with a median of 6 (range, 3–18) prior regimens. Overall, 92% of pts were penta-exposed (2 IMiDs, 2 PIs, and an mAb); 61% of pts received bridging therapy (77% were refractory to bridging therapy). Two pts had dose-limiting toxicities: grade 3 neurological event (NE) for >7 d at 300 × 106 CAR+ T cells and grade 4 neutropenia for >28 d at 450 × 106 CAR+ T cells. Key efficacy and safety outcomes are shown in the Table. Cytokine release syndrome (CRS)/NEs were managed with tocilizumab and/or steroids (78%), anakinra (14%), and/or vasopressors (6%). Grade ≥3 anemia, neutropenia, and thrombocytopenia at 29 d occurred in 21%, 55%, and 44% of pts (median time to resolution to grade ≤2 of any cytopenia, ≤2.1 mo). Grade ≥3 infections occurred in 14%. After a median follow-up (F/U) of 5.9 mo, median progression-free survival was not reached. Conclusions: Orva-cel at 300, 450, and 600 × 106 CAR+ T cells demonstrated manageable safety (CRS grade ≥3: 2%; NE grade ≥3: 4%) and compelling efficacy in heavily pretreated pts with RRMM, with a 91% objective response rate (ORR) and 39% complete response (CR)/stringent CR (sCR) rate. Updated results will be presented, including minimal residual disease, durability of response, and recommended phase 2 dose. Clinical trial information: NCT03430011 . [Table: see text]

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Hansky完成签到,获得积分10
刚刚
乖咪甜球球完成签到 ,获得积分10
3秒前
季末默相依完成签到,获得积分10
4秒前
6秒前
yiyi完成签到 ,获得积分10
6秒前
活力的鹰完成签到 ,获得积分10
6秒前
sea完成签到 ,获得积分10
8秒前
wzk完成签到,获得积分10
10秒前
linpeng发布了新的文献求助10
11秒前
LaixS完成签到,获得积分0
12秒前
要笑cc完成签到,获得积分0
14秒前
顺心妙之完成签到 ,获得积分10
14秒前
dktrrrr完成签到,获得积分10
15秒前
宣宣宣0733完成签到,获得积分0
16秒前
胡质斌完成签到,获得积分0
18秒前
维C完成签到 ,获得积分10
19秒前
大明发布了新的文献求助10
21秒前
CX完成签到,获得积分10
22秒前
22秒前
华仔的应助被科研通管家采纳,获得10
23秒前
NexusExplorer的应助被科研通管家采纳,获得10
23秒前
23秒前
不安碧灵完成签到,获得积分10
26秒前
linpeng完成签到,获得积分10
26秒前
宋艳芳完成签到,获得积分10
29秒前
快乐的幼丝完成签到 ,获得积分0
29秒前
香蕉觅云的应助被大明采纳,获得10
30秒前
CHEN完成签到 ,获得积分10
33秒前
驰骋完成签到 ,获得积分10
34秒前
maple完成签到 ,获得积分10
34秒前
阿冰完成签到 ,获得积分10
35秒前
酷炫映阳完成签到 ,获得积分10
36秒前
怡然的千儿完成签到,获得积分10
37秒前
大明完成签到,获得积分10
38秒前
harden9159完成签到,获得积分10
39秒前
43秒前
仁仁仁完成签到,获得积分10
44秒前
灯座完成签到,获得积分10
46秒前
u雨发布了新的文献求助10
47秒前
Voiceless的应助被Bin_Liu采纳,获得10
50秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180084
求助须知:如何正确求助?哪些是违规求助? 9570224
关于积分的说明 21808758
捐赠科研通 7776098
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557454
邀请新用户注册赠送积分活动 2479012